Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
about
Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantationFactors influencing long-term outcome after kidney transplantationThe use of novel diagnostics to individualize immunosuppression following transplantationMHC class I signaling: new functional perspectives for an old moleculeImmune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(®)) in renal transplant recipients.Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort studyPoor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reportsMolecules Great and Small: The Complement System.Posttransplant allosensitization in low immunological risk kidney and kidney-pancreas graft recipientsBortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trialIntravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response.An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodiesAntithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipientsClinical outcomes among renal transplant recipients with pre-transplant weakly reactive donor-specific antibodiesDifferences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response.De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection.The impact of pretransplant donor-specific antibodies on graft outcome in renal transplantation: a six-year follow-up study.The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells.Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomyDe Novo Donor-Specific HLA Antibody Development and Peripheral CD4(+)CD25(high) Cells in Kidney Transplant Recipients: A Place for Interaction?Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo.Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.Involvement of indirectly allostimulated CD4+CD43highCD45RO+ T cell proliferation in the development of chronic allograft nephropathyIncidence and clinical significance of de novo donor specific antibodies after kidney transplantation.HLA class I antibody-mediated endothelial and smooth muscle cell activation.Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial.Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.Detecting adaptive immunity: applications in transplantation monitoring.Application of Operational Tolerance Signatures Are Limited by Variability and Type of Immunosuppression in Renal Transplant Recipients: A Cross-Sectional Study.Barriers to successful transplantation of the sensitized patient.Monitoring tolerance and rejection in organ transplant recipients.Biomarkers in solid organ transplantation.Strategies for B-lymphocyte repertoire remodeling in transplantation tolerance.Immunologic monitoring in transplantation revisited.Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe?
P2860
Q26780271-CD9E08E2-DDD8-49D6-A063-56ADD0EF1816Q26825480-11588734-DBEC-476A-ABC2-5B68B5B2F3DDQ26864686-B1F20846-BF2F-4350-A25F-5891955BCC44Q27000194-EDC90610-45CC-4AFB-9C69-10ED90466528Q30403135-DA984636-5E98-4E8F-B8A0-3637660032E8Q30407134-CAF78B74-D044-459F-916F-0795B0AF9D85Q30421507-2CF95327-AFC3-4E9A-B6A6-3150C7F7D736Q33389918-85A66EC3-DA7F-4620-B21E-E652C86B4FC4Q33419651-EB8B0522-B017-4C85-BEF7-07448FBCF170Q33563056-6776D3E2-81EE-4155-BA10-639ACC00CCE1Q33584895-F304953A-B6C7-48F6-8DDD-203CB8A8F93DQ33842250-984E9C92-D9A6-492D-819E-FCB4C71D9047Q33845320-D14DB79F-B37B-4AB9-8823-1E58C86725F9Q33865743-BEE6E580-7D3A-4D8D-A75B-84C1B2C9AC86Q33930084-BE1215AB-CE75-4FFB-B20D-4B00ED516233Q34080938-69755221-6BC1-4645-B1BA-0410D4D2E469Q34796926-27F021D6-B0C9-435C-83C4-77AB397D5606Q35535173-7D3E5F7D-DC4E-48F7-8E22-EC4B0AFF7D21Q35669313-EA1AE14A-5772-4AB5-86B6-F0B162F397FAQ35865046-89974F9A-8D58-482E-8E26-D6E580A07380Q35975914-A9E8AE2A-B842-4E51-B197-32FF6D33A3FEQ36043667-0D13F9C5-0A0A-40EB-9F84-98EA04709EDFQ36126873-7A519D5D-505A-4F76-B091-7C759A009ADAQ36204503-74D090B3-3C46-4543-BFF8-3FC01EE055BAQ36246918-297F54CE-55D9-4AB1-9EE9-1522FE625CDBQ36584512-4928E820-6325-449A-96A5-75EA270AEB5DQ36822826-D1938A75-3982-4113-BD88-0A06B33D8013Q37107014-DFB04D38-4206-4C9A-BD4E-9D536DBE9AA3Q37375622-620030FB-89CE-420B-95D8-C22E08FAD35FQ37430871-DB44AE45-88F0-44FD-8812-679330527908Q37529483-2985D668-B550-4797-872E-F8232F7D9C9BQ37601515-CE6DECEB-7408-4A14-BDCC-D0D35FDC2F48Q37685073-0D4D7BFA-9031-4BB4-84A2-DA710D47D1B9Q37715369-76B14ED4-7CA1-4F04-BB90-9F6E064B9900Q37742103-192F8162-EBA2-4AA6-8B86-67257458B270Q37894733-043C4B15-9888-44A0-95E7-D81F4B068760Q37902869-603E8618-2873-4BB3-A4C1-69DD7CEE0BC6Q37938922-4BD64F87-48E6-41BF-9786-EB9E550BC85BQ37970214-D07E6F7C-901C-4A4B-AC9D-3BE4CCEA757BQ38001495-51770DE2-9A4C-4F32-A298-902AB3B2CD21
P2860
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Anti-human leukocyte antigen a ...... rejection of renal allografts.
@en
Anti-human leukocyte antigen a ...... rejection of renal allografts.
@nl
type
label
Anti-human leukocyte antigen a ...... rejection of renal allografts.
@en
Anti-human leukocyte antigen a ...... rejection of renal allografts.
@nl
prefLabel
Anti-human leukocyte antigen a ...... rejection of renal allografts.
@en
Anti-human leukocyte antigen a ...... rejection of renal allografts.
@nl
P2093
P1433
P1476
Anti-human leukocyte antigen a ...... rejection of renal allografts.
@en
P2093
Abdulgabar Salama
Andreas Kahl
Birgit Rudolph
Constanze Schönemann
Danilo Schmidt
Klemens Budde
Lutz Liefeldt
Nils Lachmann
Paul I Terasaki
P304
P356
10.1097/TP.0B013E3181A44206
P577
2009-05-01T00:00:00Z